Showing results (1981-1990 of 2,615) with videos related to
Sort By:
Pageof 262
International Clinical Psychopharmacology|June 1, 1996
The cross-national epidemiology of social phobia: a preliminary reportM M Weissman, R C Bland, G J Canino, et al.Journal of Periodontal Research|February 15, 2002
Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal diseaseNungavaram S Ramamurthy, Jing-wen Xu, John Bird, et al.Archives of Physical Medicine and Rehabilitation|May 2, 2009
A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injuryTeresa A Ashman, Joshua B Cantor, Wayne A Gordon, et al.The Journal of Craniofacial Surgery|April 21, 2001
Gene expression of transforming growth factor-beta 3 and tissue inhibitor of metalloproteinase type 1 during membranous bone healing in ratsP J Bouletreau, D Steinbrech, J A Spector, et al.Journal of the American Academy of Child and Adolescent Psychiatry|September 15, 1998
Psychopathology associated with suicidal ideation and attempts among children and adolescentsM S Gould, R King, S Greenwald, et al.Clinical and Vaccine Immunology : CVI|December 17, 2009
Immune responses in cattle inoculated with Mycobacterium bovis, Mycobacterium tuberculosis, or Mycobacterium kansasiiW R Waters, A O Whelan, K P Lyashchenko, et al.Pharmaceutics|November 11, 2022
Topical Wound Treatment with a Nitric Oxide-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in MiceMaya Ben-Yehuda Greenwald, Yu-Hang Liu, Weiye Li, et al.Frontiers in Oncology|October 20, 2023
Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinomaCaroline S Jansen, Yujin Choi, Sean T Evans, et al.Behavioural Brain Research|August 25, 2014
Pathogenic tau species drive a psychosis-like phenotype in a mouse model of Alzheimer's diseaseJ Koppel, H Jimenez, M Azose, et al.Archives of Pediatrics & Adolescent Medicine|January 9, 2003
Incidence and impact of adverse drug events in pediatric inpatientsMark T Holdsworth, Richard E Fichtl, Maryam Behta, et al.Pageof 262